Details:
The Investigational New Drug (IND) application to evaluate the efficacy of a single dose of Travelan (bovine colostrum) to prevent infectious diarrhea caused by ETEC is now active.
Lead Product(s): Bovine Colostrum
Therapeutic Area: Infections and Infectious Diseases Product Name: Travelan
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2022
Details:
Travelan (bovine colostrum) is an over the counter immune supplement that can be taken to reduce the risk of diarrhoea and reduce the symptoms of minor gastrointestinal disorders. Travelan® helps to support a healthy digestive system by supporting the gut’s immune defences.
Lead Product(s): Bovine Colostrum
Therapeutic Area: Infections and Infectious Diseases Product Name: Travelan
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
Details:
The Phase II clinical trial will evaluate the efficacy of a single dose regimen of Travelan® in a controlled human infection model (CHIM) using the enterotoxigenic Escherichia coli (ETEC) strain H10407.
Lead Product(s): Bovine Colostrum
Therapeutic Area: Infections and Infectious Diseases Product Name: Travelan
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Pharmaron
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 04, 2022
Details:
The NMRC received written guidance from FDA in relation to clinical development pathway of the new drug which the company is developing to treat moderate to severe campylobacteriosis and Enterotoxigenic Escherichia coli (ETEC) infections.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Undisclosed
Partner/Sponsor/Collaborator: US Naval Medical Research Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Details:
The self-administered nasal spray, INNA-051, is being developed to stimulate the innate immunity in the nose, where most respiratory viral infections begin. INNA-051 is a potent innate immune agonist that targets the receptor TLR2/6.
Lead Product(s): INNA-051
Therapeutic Area: Infections and Infectious Diseases Product Name: INNA-051
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
The study was conducted by an independent contract research organization to evaluate the in vitro bactericidal properties of R327 against C. perfringens and S. pyogenes.
Lead Product(s): R327
Therapeutic Area: Infections and Infectious Diseases Product Name: RECCE 327
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2021
Details:
The new financing will advance INNA-051, ENA Respiratory’s lead clinical candidate being developed to activate innate immunity in the nose, the primary site of most respiratory virus infections including COVID-19.
Lead Product(s): INNA-051
Therapeutic Area: Infections and Infectious Diseases Product Name: INNA-051
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Brandon Capital
Deal Size: $24.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 15, 2021
Details:
FDA clearance provides a pathway in the United States for use of remestemcel-L in patients with COVID-19 ARDS, under both expanded access compassionate use and in planned randomized controlled trial.
Lead Product(s): Remestemcel-L
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2020